We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
151
Tango Therapeutics
TNGX
$3.94B
$1.05M 0.06%
50,000
-90,021
-64% -$1.25M
TNYA icon
152
Tenaya Therapeutics
TNYA
$155M
$1.04M 0.06%
1,507,800
+2,500
+0.2% +$1.84K
BSAAU
153
BEST SPAC I Acquisition Corp Unit
BSAAU
$1.04M 0.06%
100,000
– –
MCK icon
154
McKesson
MCK
$104B
$1.04M 0.06%
1,200
– –
BMRN icon
155
BioMarin Pharmaceuticals
BMRN
$12.5B
$1.03M 0.06%
18,200
+5,300
+41% +$309K
ORKA
156
Oruka Therapeutics
ORKA
$6.03B
$1.02M 0.06%
20,840
– –
EA
157
DELISTED
Electronic Arts
EA
$1.01M 0.06%
4,936
– –
FULC icon
158
Fulcrum Therapeutics
FULC
$294M
$1M 0.06%
130,560
-1,123,189
-90% -$10.4M
BCRX icon
159
BioCryst Pharmaceuticals
BCRX
$2.51B
$1,000K 0.06%
105,000
+60,000
+133% +$466K
GH icon
160
Guardant Health
GH
$21.7B
$924K 0.05%
10,000
+3,000
+43% +$301K
CBIO
161
Crescent Biopharma
CBIO
$659M
$924K 0.05%
50,273
-555,727
-92% -$6.38M
CNTX icon
162
Context Therapeutics
CNTX
$35.3M
$920K 0.05%
351,094
– –
ENGN icon
163
enGene Therapeutics
ENGN
$122M
$910K 0.05%
133,686
-170,000
-56% -$1.51M
SLN
164
Silence Therapeutics
SLN
$834M
$907K 0.05%
172,157
+148,514
+628% +$818K
ARE icon
165
Alexandria Real Estate Equities
ARE
$8.87B
$905K 0.05%
19,500
+3,200
+20% +$169K
KVAC
166
CALL
DELISTED
Keen Vision Acquisition Corp
KVAC
$900K 0.05%
75,000
– –
IBIO icon
167
iBio
IBIO
$67.6M
$893K 0.05%
469,878
+64,347
+16% +$149K
BNTX icon
168
BioNTech
BNTX
$25.6B
$889K 0.05%
10,000
– –
GILD icon
169
Gilead Sciences
GILD
$181B
$885K 0.05%
6,351
-315
-5% -$44.1K
NRIX icon
170
Nurix Therapeutics
NRIX
$2.72B
$869K 0.05%
56,070
-16,000
-22% -$265K
DYN icon
171
Dyne Therapeutics
DYN
$4.68B
$861K 0.05%
47,463
+4,789
+11% +$82.6K
ISRG icon
172
Intuitive Surgical
ISRG
$132B
$844K 0.05%
1,830
+810
+79% +$410K
ANL
173
Adlai Nortye Group ADS
ANL
$890M
$816K 0.05%
+117,909
New +$788K
WW
174
WW International
WW
$162M
$793K 0.05%
57,700
+600
+1% +$13.4K
RNA
175
Atrium Therapeutics
RNA
$233M
$771K 0.05%
+57,688
New +$811K
5 6
7
8 9

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.